Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Quest, Pressure Biosciences, and More

Premium

Quest Diagnostics has promoted Tracy Cinco-Abela to be VP and treasurer. Before Cinco-Abela joined Quest in 2007 she worked for the General Motors treasurer's office, and at Quest she most recently was the company's assistant treasurer.


Pressure BioSciences has appointed Mickey Urdea to serve on its board of directors, filling the seat left by Wayne Fritzsche, who resigned last week to pursue a full-time management position at the company.

Urdea, who also will lead PBI's scientific advisory board, founded and is a managing partner of the biotech consulting firm Halteres Associates. He also founded and was CEO of Tethys Bioscience, and he helped found and served as chairman of the Catalysis Foundation for Health.


Nanosphere said this week in its fourth-quarter financial report that it has promoted Michael McGarrity to succeed William Moffitt as its new president and CEO.

The company also said it has appointed Sheli Rosenberg, Michael Ward, and McGarrity to serve on its board of directors, while Moffitt, William White, Mark Slezak, and Roy Davis have all resigned from the board. Rosenberg, who served on Nanosphere's board from 2002 to 2012, will be the new chair of the board.

McGarrity previously was VP of sales and marketing and chief commercial officer, and he has 24 years of experience in the medical devices industry, including 13 years at Stryker.


Danaher said in a filing with the Securities and Exchange Commission that Mortimer Caplin has decided not to stand for reelection to the company's board of directors and will retire after the firm's annual meeting in May.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.